Navigation Links
Snake venom studies yield insights for development of therapies for heart disease and cancer
Date:7/29/2010

n associate professor at Kogakuin University who specializes in snake toxins. "Some of those toxins prevent platelets from clotting, which can lead to profuse bleeding in snake bite victims. Others, like the one we've focused this research on, potently activate platelets, which results in blood clots. Identification of the molecular targets of many of these toxins has made an enormous contribution to our understanding of platelet activation and related diseases."

Intrigued by the then-recent discovery that elements in snake venom can promote irregular aggregation of platelets the kind that leads to clots and stroke Inoue's and Ozaki's team set out in 1997 to understand better the molecular underpinnings of those chemical reactions. They hoped that whatever they learned could be applied to the search for new therapies for irregular blood clotting caused by disease.

In 2000, another set of investigators came across a protein on the surface of platelets and dubbed it C-type lectin-like receptor 2, or CLEC-2. At the time, it remained unclear how CLEC-2 was produced or what its job was, but the team suspected it was worth further study.

After six years of research and collaborations with British investigators, the team in 2006 discovered how rhodocytin -- a molecule purified from the venom of the Southeast Asia pit viper Calloselasma rhodastoma -- binds to the CLEC-2 receptor protein on the platelet surface, spurring the platelet to clot with others like it.

Then, in another JBC "Paper of the Week" in 2007, Suzuki-Inoue and her colleagues reported how a separate molecule, called podoplanin, binds to the CLEC-2 platelet receptor protein very much like the venom molecule does. Discovered in 1990, podoplanin is a protein expressed on the surface of cancer cells, and, when bound to the CLEC-2 receptor on platelets, it spurs blood clotting, too.

"To shield themselves from the immune system, cancer cells send out a chemical, podo
'/>"/>

Contact: Angela Hopp
ahopp@asbmb.org
301-634-7389
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Good Bye, Snake Oil! Grab your Orange Juice and Daily Virus Viper™ to Safeguard Against Micro-nutrient Deficiencies
2. CIHR team grant to fund multidisciplinary breast cancer survivorship studies
3. FDA accepts historical controls for epilepsy monotherapy studies
4. Studies explore effects of war on former child soldiers
5. Pediatric clinical studies appear prone to bias, Hopkins review shows
6. Studies of womens attitudes to social egg freezing find reasons differ with age
7. Studies confirm presence, severity of pollution in national parks
8. Vitamin D Deficiency Linked to Diabetes, Metabolic Syndrome in Studies
9. 2 studies: Social factors, super users and urban emergency departments
10. MSU team studies connection between statins, tendon ruptures
11. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... LTW Cyber is an innovation hub for technology ... of addressing the needs of the global market for ... to grow while seeking collaborative opportunities with the other ... in LTW Cyber focus on secure application security, grounded ... and analyzing open source. As the hub matures, ...
(Date:3/27/2015)... March 27, 2015 The federal court ... allege the statin medication increases the risk that a ... Inc.’s Motion to Dismiss four individual cases that had ... Management Order issued in the U.S. District Court, District ... that the dismissals were warranted because the plaintiffs in ...
(Date:3/27/2015)... California (PRWEB) March 27, 2015 ... Entertainment’s EcoLuxe Lounge in the Stardust Penthouse on ... Debbie Durkin, Los Angeles’ leading sustainable product TV ... behind this unforgettable day-long event, which featured some ... and ecologically sound products and services. , “We ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
(Date:3/27/2015)... According to Health Day , on March 6th, ... (NAS) are causing alarm for Florida officials. Infants born ... a month of their lives- and can experience seizures, ... condition is precipitated by drug use during pregnancy. Unfortunately, ... medically assisted drug treatment) will also inflict NAS on ...
Breaking Medicine News(10 mins):Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2
... , MONDAY, March 7 (HealthDay News) -- Sleep tight, but ... message of a new survey that suggests many Americans might ... bedtime in front of the electronic glow of a television, ... exposure to bright light before bed disrupts sleep. But some ...
... , MONDAY, March 7 (HealthDay News) -- Genetics ... -- where fear and stress are a fact of daily ... decline, new research warns. The culprit is a specific ... that while this gene is known to play a key ...
... , MONDAY, March 7 (HealthDay News) -- Young adults ... less likely to achieve the same level of education ... Improved medical care over the past 40 years has ... surviving into adulthood. However, they carry the burden of ...
... less treatment in the American health care system than their ... dose of empathy helps close racial gaps in pain treatment. ... ease the pain of members of their own race in ... at the University of Wisconsin-Madison. "I want to be ...
... identified a critical part of the process by which ... childhood infections, respiratory syncytial virus, causes disease. ... for RSV, which in 2005 was estimated to have ... among children under five worldwide. By analyzing samples ...
... tumor growth, and naturally mounts an anti-cancer defense. Dendritic ... present them to T cells, and those "primed" T ... cells. In recent years, researchers have attempted to capitalize ... namely, by generating a pool of tumor antigen-pulsed DCs ...
Cached Medicine News:Health News:Using Electronics Before Bed May Hamper Sleep 2Health News:Using Electronics Before Bed May Hamper Sleep 3Health News:Mix of Genetics and Stress Can Impair Mental Abilities 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 3Health News:New perspective diminishes racial bias in pain treatment 2Health News:Scientists find key mechanism of childhood respiratory disease 2Health News:Scientists find key mechanism of childhood respiratory disease 3
(Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... According to a new market research report ... Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver ... Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation ... at a CAGR of 11.50% by 2019. ... through 195 pages and in-depth TOC on "Tumor Ablation ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... that it will report its 2010 year-end earnings on Thursday, April ... an analyst and investor call at 9:00 AM EDT live via ... in the conference call within the U.S. and Canada, dial (866) ... (708) 290-1340. The conference ID is 58484489. ...
... Boston Scientific Corporation (NYSE: BSX ... (FDA) approval and launch of the ION™ Paclitaxel-Eluting ... drug-eluting stent technology.  The ION Stent System incorporates ... for coronary stenting and intended to improve the ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
Medicine Products: